Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.58 | N/A | +15.08% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.58 | N/A | +15.08% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management conveyed a cautiously optimistic outlook, highlighting the positive EPS surprise. They reiterated their commitment to R&D and pipeline development.
Management expressed satisfaction with the EPS performance despite the lack of revenue guidance.
They emphasized ongoing efforts in research and development as a priority.
The team remains focused on advancing their pipeline.
Protagonist Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, rising nearly 2%. The lack of revenue data and guidance may raise some concerns among investors, but the EPS beat reflects better-than-anticipated performance in their operations. The focus on R&D suggests that the company is prioritizing long-term growth despite current financial uncertainties.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MCDONALDS CORP
Oct 30, 2023